Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Biocartis, Genomic Health to Develop IVD Version of Oncotype Prostate Test

Biocartis, Genomic Health to Develop IVD Version of Oncotype Prostate Test

Dec 04, 2018
|
staff reporter

NEW YORK (GenomeWeb) – Biocartis said yesterday that it has signed a development agreement with Genomic Health to develop an in vitro diagnostic version of the Oncotype DX Genomic Prostate Score (GPS) Test.

The agreement expands on a previous partnership to develop an IVD version of Genomic Health's Oncotype DX Breast Recurrence Score test on Biocarts' Idylla platform.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
23
Featured Webinar

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Feb
24
Featured Webinar

Case Study: Rapid Development and Manufacturing Scaleup of a Point-of-Care COVID-19 Test

Sponsored by
SCHOTT MINIFAB

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints. 

Feb
26
Featured Webinar

Responding to Emerging SARS-CoV-2 Variants: The Impact on Existing Diagnostic Testing and the Clinical Utility of Differentiation Assays

As new variants of SARS-CoV-2 circulate around the globe, there is growing concern among clinical laboratories that these variants may impact their ability to accurately detect the virus.  

What's Popular?

In PCR

  1. CDC Study Finds Abbott BinaxNow SARS-CoV-2 Antigen Test Less Sensitive Than PCR, But Still Useful

  2. Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M

  3. Bio-Rad, United Biomedical Get FDA Emergency Use Authorizations for Coronavirus Tests

  4. Lucira Health Files for $115M IPO

  5. MiRxes Receives CE Mark, Singapore Regulatory Approval for Multiplex SARS-CoV-2, Flu Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.